688621 阳光诺和
已收盘 05-29 15:00:01
资讯
新帖
简况
每周股票复盘：阳光诺和（688621）STC008项目权益转让终止
证券之星 · 03:20
每周股票复盘：阳光诺和（688621）STC008项目权益转让终止
阳光诺和(688621.SH)拟500万元认购启真智康基金份额
智通财经 · 05-29 17:25
阳光诺和(688621.SH)拟500万元认购启真智康基金份额
每周股票复盘：阳光诺和（688621）STC009注射液临床试验申请获受理
证券之星 · 05-24
每周股票复盘：阳光诺和（688621）STC009注射液临床试验申请获受理
阳光诺和(688621.SH)：在研项目STC009注射液的临床试验申请获得受理
智通财经 · 05-22
阳光诺和(688621.SH)：在研项目STC009注射液的临床试验申请获得受理
阳光诺和（688621）披露2025年年度股东会决议公告，5月15日股价下跌1.13%
证券之星 · 05-15
阳光诺和（688621）披露2025年年度股东会决议公告，5月15日股价下跌1.13%
阳光诺和最新公告：拟向全资子公司增资7000万元
证券之星 · 05-15
阳光诺和最新公告：拟向全资子公司增资7000万元
5月11日阳光诺和涨5.11%，融通健康产业灵活配置混合A/B基金重仓该股
证券之星 · 05-11
5月11日阳光诺和涨5.11%，融通健康产业灵活配置混合A/B基金重仓该股
30余家药企一季报出炉：有人狂赚有人亏 行业分化加剧
21世纪经济报道 · 04-27
30余家药企一季报出炉：有人狂赚有人亏 行业分化加剧
股市必读：阳光诺和年报 - 第四季度单季净利润同比增长234.02%
证券之星 · 04-27
股市必读：阳光诺和年报 - 第四季度单季净利润同比增长234.02%
每周股票复盘：阳光诺和（688621）股东户数增11.58%，净利降30.25%
证券之星 · 04-26
每周股票复盘：阳光诺和（688621）股东户数增11.58%，净利降30.25%
阳光诺和(688621)3月31日股东户数0.8万户，较上期增加11.58%
证券之星 · 04-24
阳光诺和(688621)3月31日股东户数0.8万户，较上期增加11.58%
图解阳光诺和年报：第四季度单季净利润同比增长234.02%
证券之星 · 04-24
图解阳光诺和年报：第四季度单季净利润同比增长234.02%
每周股票复盘：阳光诺和（688621）ABA001注射液获临床试验批准
证券之星 · 04-05
每周股票复盘：阳光诺和（688621）ABA001注射液获临床试验批准
阳光诺和（688621）披露ABA001注射液获得药物临床试验批准通知书，4月3日股价下跌4.68%
证券之星 · 04-03
阳光诺和（688621）披露ABA001注射液获得药物临床试验批准通知书，4月3日股价下跌4.68%
阳光诺和(688621.SH)：ABA001注射液获药物临床试验批准
智通财经 · 04-02
阳光诺和(688621.SH)：ABA001注射液获药物临床试验批准
3月27日阳光诺和涨5.00%，融通健康产业灵活配置混合A/B基金重仓该股
证券之星 · 03-27
3月27日阳光诺和涨5.00%，融通健康产业灵活配置混合A/B基金重仓该股
3月23日阳光诺和跌7.38%，融通健康产业灵活配置混合A/B基金重仓该股
证券之星 · 03-23
3月23日阳光诺和跌7.38%，融通健康产业灵活配置混合A/B基金重仓该股
阳光诺和最新公告：子公司签署STC007注射液技术许可协议
证券之星 · 03-20
阳光诺和最新公告：子公司签署STC007注射液技术许可协议
阳光诺和（688621）披露终止重大资产重组事项内幕信息知情人自查报告，3月13日股价下跌0.13%
证券之星 · 03-13
阳光诺和（688621）披露终止重大资产重组事项内幕信息知情人自查报告，3月13日股价下跌0.13%
阳光诺和：STC007注射液针对术后疼痛的临床试验正在按既定方案稳步推进
证券日报 · 03-13
阳光诺和：STC007注射液针对术后疼痛的临床试验正在按既定方案稳步推进
暂无数据
公司概况
公司名称：
北京阳光诺和药物研究股份有限公司
所属行业：
研究和试验发展
上市日期：
2021-06-21
主营业务：
北京阳光诺和药物研究股份有限公司的主营业务是为国内医药企业和科研机构提供全过程的一站式药物研发服务。公司的主要产品是仿制药药学研究服务、临床试验及生物分析服务、创新药、改良型新药研发服务、知识产权授权、权益分成。
发行价格：
26.89
{"stockData":{"symbol":"688621","market":"SH","secType":"STK","nameCN":"阳光诺和","latestPrice":54,"timestamp":1780038001000,"preClose":55.27,"halted":0,"volume":1841850,"delay":0,"changeRate":-0.023,"floatShares":112000000,"shares":112000000,"eps":1.7404,"marketStatus":"已收盘","change":-1.27,"latestTime":"05-29 15:00:01","open":56,"high":56.27,"low":53.02,"amount":100000000,"amplitude":0.0588,"askPrice":54.1,"askSize":103,"bidPrice":54,"bidSize":104,"shortable":0,"etf":0,"ttmEps":1.7404,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780277400000},"marketStatusCode":5,"adr":0,"adjPreClose":55.27,"symbolType":"stock_kcb","openAndCloseTimeList":[[1780018200000,1780025400000],[1780030800000,1780038000000]],"highLimit":60.8,"lowLimit":49.74,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":112000000,"isCdr":false,"pbRate":4.82,"roa":"--","peRate":31.02735,"roe":"1.67%","epsLYR":1.86,"committee":-0.336226,"marketValue":6048000000,"turnoverRate":0.0164,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-06-01。","afterMarket":{"amount":0,"volume":0,"close":54,"buyVolume":0,"sellVolume":0,"time":1780040038866,"indexStatus":"已收盘 05-29 15:30:00","preClose":55.27},"floatMarketCap":6048000000},"requestUrl":"/m/hq/s/688621/tweets","defaultTab":"tweets","newsList":[{"id":"2639604987","title":"每周股票复盘：阳光诺和（688621）STC008项目权益转让终止","url":"https://stock-news.laohu8.com/highlight/detail?id=2639604987","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639604987?lang=zh_cn&edition=full","pubTime":"2026-05-31 03:20","pubTimestamp":1780168821,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，阳光诺和报收于54.0元，较上周的56.25元下跌4.0%。本周，阳光诺和5月25日盘中最高价报58.77元。公司公告汇总关于STC008注射液签署《技术开发合同补充协议》的进展公告北京阳光诺和药物研究股份有限公司与星浩控股、亚太药业于2026年4月签订STC008注射液《技术开发合同补充协议》，约定星浩控股将STC008项目权益转让给亚太药业。STC008项目权益仍由星浩控股持有。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100000940.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639362569","title":"阳光诺和(688621.SH)拟500万元认购启真智康基金份额","url":"https://stock-news.laohu8.com/highlight/detail?id=2639362569","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639362569?lang=zh_cn&edition=full","pubTime":"2026-05-29 17:25","pubTimestamp":1780046736,"startTime":"0","endTime":"0","summary":"智通财经APP讯，阳光诺和(688621.SH)发布公告，公司于近日与北京浙商华盈创业投资管理有限公司及其他合伙人签署合伙协议，以自有资金500万元认购杭州启真智康股权投资合伙企业(有限合伙)(简称“启真智康基金”)份额，担任有限合伙人，占合伙企业总认缴出资额的18.87%，由于启真智康基金尚处于募集阶段，公司持有的份额比例以最终募集完成情况为准。启真智康基金专项投资于杭州翊圣生物科技有限公司(简称“翊圣生物”)，翊圣生物聚焦慢性炎症与重大慢病新药研发，从慢性炎症的角度为相关疾病发现防治新靶点和新药物。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447783.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637376472","title":"每周股票复盘：阳光诺和（688621）STC009注射液临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2637376472","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637376472?lang=zh_cn&edition=full","pubTime":"2026-05-24 05:16","pubTimestamp":1779570975,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，阳光诺和报收于56.25元，较上周的56.18元上涨0.12%。本周，阳光诺和5月21日盘中最高价报59.3元。本周关注点公司公告汇总：STC009注射液临床试验申请获国家药监局受理公司公告汇总自愿披露关于STC009注射液临床试验申请获得受理的公告北京阳光诺和药物研究股份有限公司全资子公司成都诺和晟泰生物科技有限公司收到国家药品监督管理局签发的《受理通知书》，其在研项目STC009注射液的临床试验申请已获受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400001708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637012391","title":"阳光诺和(688621.SH)：在研项目STC009注射液的临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2637012391","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637012391?lang=zh_cn&edition=full","pubTime":"2026-05-22 16:17","pubTimestamp":1779437831,"startTime":"0","endTime":"0","summary":"智通财经APP讯，阳光诺和 发布公告，近日，公司全资子公司成都诺和晟泰生物科技有限公司收到国家药品监督管理局核准签发的《受理通知书》，在研项目STC009注射液的临床试验申请获得受理。本次递交的STC009注射液为1类创新药，拟申报适应症为继发性甲状旁腺功能亢进症。STC009注射液是诺和晟泰依托公司独有的iCVETide多肽新药发现平台开发的钙离子敏感受体多肽激动剂，药物分子发现的相关研究成果已发表于国际顶级期刊Journalof Medicinal Chemistry。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445019.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635358180","title":"阳光诺和（688621）披露2025年年度股东会决议公告，5月15日股价下跌1.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635358180","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635358180?lang=zh_cn&edition=full","pubTime":"2026-05-15 22:52","pubTimestamp":1778856734,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，阳光诺和报收于56.18元，较前一交易日下跌1.13%，最新总市值为62.92亿元。该股当日开盘56.81元，最高57.49元，最低55.8元，成交额达1.04亿元，换手率为1.64%。近日，阳光诺和披露《2025年年度股东会决议公告》。本次会议无被否决议案，表决程序合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500044481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635108901","title":"阳光诺和最新公告：拟向全资子公司增资7000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2635108901","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635108901?lang=zh_cn&edition=full","pubTime":"2026-05-15 19:39","pubTimestamp":1778845163,"startTime":"0","endTime":"0","summary":"阳光诺和(688621.SH)公告称，为满足公司全资子公司广东诺和智肽生物科技有限公司（简称“诺和智肽”）的正常经营需要，公司拟以自有资金7000万元向诺和智肽进行增资。增资完成后，诺和智肽注册资本将由3000万元增加至1亿元，仍为公司全资子公司。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500038010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634409629","title":"5月11日阳光诺和涨5.11%，融通健康产业灵活配置混合A/B基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2634409629","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634409629?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:32","pubTimestamp":1778488358,"startTime":"0","endTime":"0","summary":"证券之星消息，5月11日阳光诺和涨5.11%，收盘报60.44元，换手率3.19%，成交量3.58万手，成交额2.13亿元。重仓阳光诺和的公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共7家，其中持有数量最多的公募基金为融通基金的融通健康产业灵活配置混合A/B。该公募基金现任基金经理为万民远。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100021973.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630395435","title":"30余家药企一季报出炉：有人狂赚有人亏 行业分化加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=2630395435","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630395435?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:29","pubTimestamp":1777289340,"startTime":"0","endTime":"0","summary":"近日，A股医药板块迎来一季度财报密集披露期，包括阳光诺和、华东医药、重药控股、圣诺生物、我武生物、一品红、丽珠集团、浙江医药、济川药业、科源制药、千红制药等在内的超30家药企集中交出第一季度成绩单。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604273720459429.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604273720459429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0191","BK0216","BK0071","BK0196","BK0183","301281","688621","688117","06978","BK0188","BK0028","300723","BK1161","002550","BK0250","BK0209","LU2328871848.SGD","BK0187","BK0132","BK0175","BK0239","000950","LU1969619763.USD","600216","000963","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630339855","title":"股市必读：阳光诺和年报 - 第四季度单季净利润同比增长234.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630339855","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630339855?lang=zh_cn&edition=full","pubTime":"2026-04-27 04:15","pubTimestamp":1777234513,"startTime":"0","endTime":"0","summary":"来自股本股东变化：截至2026年3月31日，公司股东户数环比增长11.58%，户均持股数量下降至1.4万股。来自业绩披露要点：2025年第四季度公司单季度归母净利润同比增长234.02%，驱动全年盈利稳步提升。股本股东变化股东户数变动近日阳光诺和披露，截至2026年3月31日公司股东户数为7988.0户，较12月31日增加829.0户，增幅为11.58%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700005794.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630578804","title":"每周股票复盘：阳光诺和（688621）股东户数增11.58%，净利降30.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630578804","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630578804?lang=zh_cn&edition=full","pubTime":"2026-04-26 03:35","pubTimestamp":1777145714,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，阳光诺和报收于58.78元，较上周的64.35元下跌8.66%。本周，阳光诺和4月20日盘中最高价报65.03元。阳光诺和当前最新总市值65.83亿元，在医疗服务板块市值排名27/51，在两市A股市值排名2812/5200。本周关注点股本股东变化：股东户数较上期增加11.58%，户均持股下降至1.4万股业绩披露要点：归母净利润2063.1万元，同比下降30.25%股本股东变化股东户数变动截至2026年3月31日，公司股东户数为7988.0户，较12月31日增加829.0户，增幅11.58%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600001480.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629814689","title":"阳光诺和(688621)3月31日股东户数0.8万户，较上期增加11.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629814689","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629814689?lang=zh_cn&edition=full","pubTime":"2026-04-24 17:31","pubTimestamp":1777023107,"startTime":"0","endTime":"0","summary":"证券之星消息，近日阳光诺和披露，截至2026年3月31日公司股东户数为7988.0户，较12月31日增加829.0户，增幅为11.58%。在医疗服务行业个股中，阳光诺和股东户数低于行业平均水平，截至3月31日，医疗服务行业平均股东户数为4.71万户。从股价来看，2025年12月31日至2026年3月31日，阳光诺和区间涨幅为3.27%，在此期间股东户数增加829.0户，增幅为11.58%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400052665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629542238","title":"图解阳光诺和年报：第四季度单季净利润同比增长234.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629542238","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629542238?lang=zh_cn&edition=full","pubTime":"2026-04-24 02:00","pubTimestamp":1776967244,"startTime":"0","endTime":"0","summary":"证券之星消息，阳光诺和2025年年报显示，当年度公司主营收入12.22亿元，同比上升13.33%；归母净利润2.04亿元，同比上升14.91%；扣非净利润1.92亿元，同比上升16.05%；其中2025年第四季度，公司单季度主营收入3.66亿元，同比上升126.52%；单季度归母净利润4058.06万元，同比上升234.02%；单季度扣非净利润3807.6万元，同比上升203.99%；负债率46.01%，投资收益496.83万元，财务费用1394.57万元，毛利率54.12%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400004923.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625616871","title":"每周股票复盘：阳光诺和（688621）ABA001注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2625616871","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625616871?lang=zh_cn&edition=full","pubTime":"2026-04-05 01:43","pubTimestamp":1775324593,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，阳光诺和报收于65.57元，较上周的64.68元上涨1.38%。本周，阳光诺和4月1日盘中最高价报69.77元。阳光诺和当前最新总市值73.44亿元，在医疗服务板块市值排名27/51，在两市A股市值排名2451/5193。本周关注点公司公告汇总：ABA001注射液获药物临床试验批准通知书公司公告汇总北京阳光诺和药物研究股份有限公司及全资子公司北京阿尔纳科技有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意 ABA001注射液开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000297.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624727656","title":"阳光诺和（688621）披露ABA001注射液获得药物临床试验批准通知书，4月3日股价下跌4.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624727656","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624727656?lang=zh_cn&edition=full","pubTime":"2026-04-03 17:22","pubTimestamp":1775208174,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，阳光诺和报收于65.57元，较前一交易日下跌4.68%，最新总市值为73.44亿元。公司于近日披露《关于ABA001注射液获得药物临床试验批准通知书的公告》。公告显示，北京阳光诺和药物研究股份有限公司及全资子公司北京阿尔纳科技有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意 ABA001注射液开展临床试验。药品后续仍需开展临床试验及上市审批，存在研发风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300034279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624579620","title":"阳光诺和(688621.SH)：ABA001注射液获药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2624579620","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624579620?lang=zh_cn&edition=full","pubTime":"2026-04-02 16:00","pubTimestamp":1775116815,"startTime":"0","endTime":"0","summary":"智通财经APP讯，阳光诺和(688621.SH)公告，公司及全资子公司北京阿尔纳科技有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研项目ABA001注射液的临床试验申请获得批准，ABA001注射液拟申报适应症为高血压。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"阳光诺和(688621.SH)：ABA001注射液获药物临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622849396","title":"3月27日阳光诺和涨5.00%，融通健康产业灵活配置混合A/B基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2622849396","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622849396?lang=zh_cn&edition=full","pubTime":"2026-03-27 16:14","pubTimestamp":1774599257,"startTime":"0","endTime":"0","summary":"证券之星消息，3月27日阳光诺和涨5.00%，收盘报64.68元，换手率2.62%，成交量2.94万手，成交额1.88亿元。重仓阳光诺和的公募基金请见下表：该股最近90天内共有4家机构给出评级，买入评级4家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共9家，其中持有数量最多的公募基金为融通基金的融通健康产业灵活配置混合A/B。该公募基金现任基金经理为万民远。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700033408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621680776","title":"3月23日阳光诺和跌7.38%，融通健康产业灵活配置混合A/B基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2621680776","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621680776?lang=zh_cn&edition=full","pubTime":"2026-03-23 16:42","pubTimestamp":1774255352,"startTime":"0","endTime":"0","summary":"证券之星消息，3月23日阳光诺和跌7.38%创60日新低，收盘报55.81元，换手率2.22%，成交量2.49万手，成交额1.43亿元。重仓阳光诺和的公募基金请见下表：该股最近90天内共有5家机构给出评级，买入评级5家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共9家，其中持有数量最多的公募基金为融通基金的融通健康产业灵活配置混合A/B。该公募基金现任基金经理为万民远。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300025446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620784567","title":"阳光诺和最新公告：子公司签署STC007注射液技术许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2620784567","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620784567?lang=zh_cn&edition=full","pubTime":"2026-03-20 17:30","pubTimestamp":1773999014,"startTime":"0","endTime":"0","summary":"阳光诺和(688621.SH)公告称，公司全资子公司诺和晟泰与信立泰(002294.SZ)签署《技术许可及合作开发协议》，授予信立泰STC007注射液在中国市场所有瘙痒适应症的独家许可权益。根据协议，诺和晟泰将获得首付款及研发里程碑款合计最高1.25亿元；若产品上市后净销售额达标，还可获得累计最高7.25亿元的销售里程碑款及按比例销售提成。该合作预计将对公司未来业绩产生积极影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000030585.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619130681","title":"阳光诺和（688621）披露终止重大资产重组事项内幕信息知情人自查报告，3月13日股价下跌0.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619130681","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619130681?lang=zh_cn&edition=full","pubTime":"2026-03-13 22:26","pubTimestamp":1773411987,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘，阳光诺和报收于61.72元，较前一交易日下跌0.13%，最新总市值为69.13亿元。近日，北京阳光诺和药物研究股份有限公司发布《关于终止发行股份及可转换公司债券购买资产并募集配套资金暨关联交易事项相关内幕信息知情人自查期间买卖股票情况自查报告的公告》。根据中国证券登记结算有限责任公司出具的查询证明，部分内幕信息知情人在自查期间存在股票买卖行为，均已作出无内幕交易的说明及承诺。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300041694.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619191065","title":"阳光诺和：STC007注射液针对术后疼痛的临床试验正在按既定方案稳步推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2619191065","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619191065?lang=zh_cn&edition=full","pubTime":"2026-03-13 19:12","pubTimestamp":1773400320,"startTime":"0","endTime":"0","summary":"登录新浪财经APP 搜索【信披】查看更多考评等级\n 证券日报网讯 3月13日，阳光诺和在互动平台回答投资者提问时表示，STC007注射液针对术后疼痛的临床试验正在按既定方案稳步推进，目前各项临床工作有序开展，相关进展符合预期。关于上市申请时间，需根据临床试验数据结果、统计分析及注册申报准备情况综合确定，公司将根据法律法规要求及时履行信息披露义务。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-13/doc-inhqvxrh1015398.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-13/doc-inhqvxrh1015398.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780239634058,"stockEarnings":[{"period":"1week","weight":-0.04},{"period":"1month","weight":-0.0779},{"period":"3month","weight":-0.173},{"period":"6month","weight":-0.1837},{"period":"1year","weight":0.0199},{"period":"ytd","weight":-0.1311}],"compareEarnings":[{"period":"1week","weight":-0.0108},{"period":"1month","weight":-0.0095},{"period":"3month","weight":-0.0227},{"period":"6month","weight":0.0463},{"period":"1year","weight":0.2096},{"period":"ytd","weight":0.0251}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京阳光诺和药物研究股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"7988人(较上一季度增加11.58%)","perCapita":"14021股","listingDate":"2021-06-21","address":"北京市昌平区科技园区双营西路79号院7号楼一层","registeredCapital":"11200万元","survey":" 北京阳光诺和药物研究股份有限公司的主营业务是为国内医药企业和科研机构提供全过程的一站式药物研发服务。公司的主要产品是仿制药药学研究服务、临床试验及生物分析服务、创新药、改良型新药研发服务、知识产权授权、权益分成。","listedPrice":26.89},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阳光诺和(688621)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阳光诺和(688621)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阳光诺和,688621,阳光诺和股票,阳光诺和股票老虎,阳光诺和股票老虎国际,阳光诺和行情,阳光诺和股票行情,阳光诺和股价,阳光诺和股市,阳光诺和股票价格,阳光诺和股票交易,阳光诺和股票购买,阳光诺和股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阳光诺和(688621)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阳光诺和(688621)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}